SLC5A2 and type 2 diabetes mellitus: The present meta-analysis includes the most recent published large RCTs (EMPEROR-Preserved, EMPEROR-Reduced, DELIVER, DAPA-HF) thus providing the most contemporary assessment of the total available evidence for SGLT-2 inhibitor therapy and cardiac function or health status outcomes in CHF patients with or without T2D.